Regulatory Updates
🇺🇸 FDA Page 6FDA news and analysis for pharmaceutical BD, investment, and market access · 12 articles on this page
Track global pharma regulatory policy changes, FDA, EMA, and other agency guidelines impacting drug development and market access. Stay ahead.
Showing 61–72 of 382 articles
Rx Rundown: Pfizer, Hikma Pharmaceuticals, NewLimit — Drug Approvals & Catalyst Tracker
MIRA Pharma Consolidates Global Rights to MIRA-55 and SKNY-1
4 Biotech Stocks Investors Should Watch in 2026: Market Analysis
Alabama Board of Medical Examiners Issues Warning on Non-FDA-Approved Peptides: What Pharma Teams Need to Know
Vertex Announces FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy
Aurobindo Pharma OAI Classification: Implications for Drug Approvals
Lee, Tuberville Introduce Protections for Homeopathic Medicine with FDA Approval Framework
Daraxonrasib Doubles Survival in Pancreatic Cancer: What Pharma Teams Need to Know
FDA Approves Ensitrelvir (XOCOVA) as First Oral Option for COVID-19 Post-Exposure Prophylaxis
FDA Priority Review Voucher Program: Will Makary's Initiative Survive?
Tip Sheet GLP-1s and Cancer: Key Insights for Pharma BD and Investors
Grail’s Galleri Trial Missed Its Primary Endpoint: What BD Teams and Investors Need to Know